Livestock customers under economic pressure increasingly want guarantees that feed products will deliver animal performance, and suppliers of plant-based additives are being pushed to prove their value. In an interview with Expana at EuroTier 2026 last week, Kurt Wegleitner, Managing Director of Phytobiotics shared his thoughts on how to frame the benefits of phytogenic feed additives in that global context.
Asked about the biggest obstacle to wider adoption of plant-based specialty feed additives, Wegleitner said the most important task is building trust in the economic benefit.
“I would not start with the product price, but with the question of whether customers can see what the solution contributes under their own conditions,” he said. “If we answer that convincingly, a cost discussion becomes an investment decision. That takes solid trial results, a transparent economic assessment and good technical support.”
Looking to 2027, Wegleitner said he views the year for Phytobiotics and phytogenic feed additives “with great confidence.” The company, he said, will make better use of existing strengths, position the third generation of its flagship product (Sangrovit) consistently in the market, and invest where real customer demand and a sound economic outlook come together. He said a lot of focus will be placed on the commercial rollout of innovations, technical proximity to customers and reliable processes.
“The goal for 2027 is not simply to get bigger, but to get stronger through focus, innovation and economic discipline.”
Over the years, Phytobiotics has invested in manufacturing in Germany, at Neuendettelsau, Bavaria, and operates additional production facilities internationally, including in Londrina, Brazil, and in China at Jintan, Changzhou, Jiangsu province, and Duyun, Guizhou province. The company has previously set out growth plans for China, including investment in local additive and premix production.
“China remains a market for long-term commitment and patience,” Wegleitner said. “Our local production base lets us combine international expertise with proximity to Chinese customers. I would not measure the next phase by capacity alone, but by how well we turn our presence into lasting customer relationships and profitable business. We want to win on quality, demonstrable benefit and reliable cooperation, not on price.”
Wegleitner listed his priorities for the next stage in China as a focused portfolio, strong technical advice and close alignment between the local organization and the international team.
Be it for China as for any other future capacity investments, Wegleitner said additional capacity “makes sense when demand, utilization and execution fit together.”
In February 2026, Phytobiotics introduced the third generation of Sangrovit in an optimized formulation with a protective delivery mechanism. In June, it obtained a new European patent for the product. Wegleitner said the launch “strengthens the company’s position as an innovation partner in animal nutrition.”
“Over the next two years, I want to deepen existing partnerships and win new customers,” he said. “We have already started informing customers about the third generation and the patent. Now we need to combine science, practical advice and a clear view of the economics.”
Written by Simon Duke